Pharmacologic Approaches to Weight Management: Recent Gains and Shortfalls in Combating Obesity

Current Atherosclerosis Reports

Volumn 18, Issue 7, 2016, Pages

  Saunders, Katherine H ^a   Kumar, Rekha B ^a   Igel, Leon I ^a   Aronne, Louis J ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Clinical trials; Obesity; Pharmacotherapy; Type 2 diabetes; Weight loss; Weight management

Indexed keywords

AMFEBUTAMONE PLUS NALTREXONE; BELORANIB; CANAGLIFLOZIN; EXENDIN 4; LIRAGLUTIDE; LORCASERIN; PHENTERMINE; PHENTERMINE PLUS TOPIRAMATE; PLACEBO; SEROTONIN 2C RECEPTOR; ANTIOBESITY AGENT;

ATTENTION DISTURBANCE; BODY WEIGHT MANAGEMENT; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CONSTIPATION; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG APPROVAL; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG THERAPY; DRUG TOLERABILITY; DYSGEUSIA; FAT MASS; HEADACHE; HUMAN; INSOMNIA; IRRITABILITY; NAUSEA; OBESITY; OUTCOME ASSESSMENT; PARESTHESIA; PATIENT COUNSELING; RECOMMENDED DRUG DOSE; REVIEW; RISK REDUCTION; SIDE EFFECT; VOMITING; WAIST CIRCUMFERENCE; WEIGHT CHANGE; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA; BODY WEIGHT; COMORBIDITY; COMPLICATION; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS;

ANTI-OBESITY AGENTS; BODY WEIGHT; COMORBIDITY; DIABETES MELLITUS, TYPE 2; HUMANS; OBESITY; WEIGHT LOSS;

EID: 84971612134     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-016-0589-y     Document Type: Review

References (49)

1. Ogden CL, Carroll MD, Fryar CD, Flegal KM. Prevalence of obesity among adults and youth: united states, 2011–2014. NCHS Data Brief. 2015;219:1–8.
2. Ogden CL, Flegal KM. Changes in terminology for childhood overweight and obesity. Natl Health Stat Report. 2010;25:1–5.
3. Finkelstein EA, Trogdon JG, Cohen JW, Dietz W. Annual medical spending attributable to obesity: payer-and service-specific estimates. Health Aff (Millwood). 2009;28(5):w822–31.
4. Trogdon JG, Finkelstein EA, Hylands T, Dellea PS, Kamal-Bahl SJ. Indirect costs of obesity: a review of the current literature. Obes Rev. 2008;9(5):489–500.
5. Thompson D, Edelsberg J, Kinsey KL, Oster G. Estimated economic costs of obesity to U.S. business. Am J Health Promot. 1998;13:120–7.
6. Wolf AM, Colditz GA. The cost of obesity: the US perspective. Pharmacoeconomics. 1994;5:34–7.
7. Lovren F, Teoh H, Verma S. Obesity and atherosclerosis: mechanistic insights. Can J Cardiol. 2015;31(2):177–83.
8. Magkos F, Fraterrigo G, Yoshino J. Effects of moderate and subsequent progressive weight loss on metabolic function and adipose tissue biology in humans with obesity. Cell Metab. 2016;S1550-4131(16):30053–5.
9. Wing RR, Lang W, Wadden TA, et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011;34(7):1481–6.
10. The Look AHEAD Research Group. The look AHEAD study: A description of the lifestyle intervention and the evidence supporting it. Obesity. 2006;14:737–52.
11. Diabetes Prevention Program (DPP) Research Group. The diabetes prevention program (DPP): description of lifestyle intervention. Diabetes Care. 2002;25:2165–71.
12. Hinkle W, Cordell M, Leibel R, Rosenbaum M, Hirsch J. Effects of reduced weight maintenance and leptin repletion on functional connectivity of the hypothalamus in obese humans. PLoS One. 2013;8(3):e59114.
13. Rosenbaum M, Goldsmith R, Bloomfield D. Low-dose leptin reverses skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced weight. J Clin Invest. 2005;115(12):3579–86.
14. Rosenbaum M, Hirsch J, Gallagher DA, Leibel RL. Long-term persistence of adaptive thermogenesis in subjects who have maintained a reduced body weight. Am J Clin Nutr. 2008;88(4):906–12.
15. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol. 2014;63((25 Pt B)):2985–3023. This publication denotes the first clinical practice guidelines for the management of adults with overweight and obesity. These guidelines were drafted by a task force of experts from the American College of Cardiology, American Heart Association and The Obesity Society.
16. Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(2):342–62. This publication denotes the first clinical practice guidelines for the pharmacologic management of obesity. These guidelines were drafted by an Endocrine Society-appointed task force of experts, and were co-sponsored by the European Society of Endocrinology and The Obesity Society.
17. American Medical Association. Policy H-440.842. Recognition of Obesity as a Disease. 2013.
18. Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring). 2012;20(2):330–42.
19. Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9774):1341–52.
20. Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012;95(2):297–308.
21. Smith SR, Weissman NJ, Anderson CM, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010;363(3):245–56.
22. Fidler MC, Sanchez M, Raether B, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab. 2011;96(10):3067–77.
23. O’Neil PM, Smith SR, Weissman NJ, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring). 2012;20(7):1426–36.
24. Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376(9741):595–605.
25. Apovian CM, Aronne L, Rubino D, et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring). 2013;21(5):935–43.
26. Wadden TA, Foreyt JP, Foster GD, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring). 2011;19(1):110–20.
27. Hollander P, Gupta AK, Plodkowski R, et al. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. 2013;36(12):4022–9.
28. Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11–22.
29. Davies MJ, Bergenstal R, Bode B, et al. Efficacy of Liraglutide for weight loss among patients with type 2 diabetes: the SCALE Diabetes randomized clinical trial. JAMA. 2015;314(7):687–99.
30. Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes (Lond). 2013;37(11):1443–51.
31. Thomas EA, Mcnair B, Bechtell JL, Ferland A, Cornier MA, Eckel RH. Greater hunger and less restraint predict weight loss success with phentermine treatment. Obesity (Silver Spring). 2016;24(1):37–43.
32. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 1997;337(9):581–8.
33. Wadden TA, Berkowitz RI, Womble LG, et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med. 2005;353(20):2111–20.
34. Digenio AG, Mancuso JP, Gerber RA, Dvorak RV. Comparison of methods for delivering a lifestyle modification program for obese patients: a randomized trial. Ann Intern Med. 2009;150(4):255–62.
35. Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009;32(1):84–90.
36. Hughes TE, Kim DD, Marjason J, Proietto J, Whitehead JP, Vath JE. Ascending dose-controlled trial of beloranib, a novel obesity treatment for safety, tolerability, and weight loss in obese women. Obesity (Silver Spring). 2013;21(9):1782–8.
37. Kim DD, Krishnarajah J, Lillioja S, et al. Efficacy and safety of beloranib for weight loss in obese adults: a randomized controlled trial. Diabetes Obes Metab. 2015;17(6):566–72.
38. Zafgen Inc. Zafgen’s pivotal phase 3 trial of beloranib in Prader-Willi syndrome achieves co-primary efficacy endpoints. http://ir.zafgen.com/releasedetail.cfm?ReleaseID=950876. Accessed February 26, 2016.
39. Zafgen Inc. Zafgen announces positive results from phase 2 clinical trial of beloranib in hypothalamic injury associated obesity. http://ir.zafgen.com/releasedetail.cfm?releaseid=889999. Accessed March 8, 2016.
40. Zafgen, Inc. Zafgen provides clinical update on Beloranib. http://ir.zafgen.com/releasedetail.cfm?releaseid=945102. Accessed February 26, 2016.
41. Lomaira KVK Tech, Inc. http://kvktech.com/lomaira/ Accessed Feburary 27, 2016.
42. Smith SR, Garvey WT, Greenway F, et al. Combination Weight Management (WM) Pharmacotherapy with Lorcaserin (LOR) and Immediate Release (IR) Phentermine (phen) [abstract]. Poster presented at Obesity Week. Boston; 2014.
43. Aronne LJ. A practical guide to drug-induced weight gain. Minneapolis: McGraw-Hill; 2002.
44. Top-Line Data Show CV Benefit for Liraglutide in Type 2 Diabetes. Miriam E Tucker. Medscape Medical News. WebMD LLC. http://www.medscape.com/viewarticle/859905. Accessed March 8, 2016.
45. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28. EMPA-REG OUTCOME is the first trial investigating a medication for type 2 diabetes which demonstrates both weight loss and improved cardiovascular outcomes in high-risk patients.
46. Dungan KM, Povedano ST, Forst T, et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet. 2014;384(9951):1349–57.
47. Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013;159:262–74.
48. Stenlöf K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013;15:372–82.
49. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):140–9.